Biological and Pharmaceutical Bulletin · 2009 · 34 citations · 33 references
PharmacyPharmacokineticsPharmacologyDrug MetabolismHepatic PharmacokineticsHepatologyBiliary ExcretionBiliary Excretion Of MetabolitesHepatic ClearanceHepatic Drug AbsorptionLiver DiseasePharmacokinetics In Liver DiseaseBile Duct ObstructionBiliary Elimination KineticsExtrahepatic CholestasisHepatic Drug TransportersHepatic TransportersObstructive CholestasisRenal Drug ExcretionRenal Elimination Kinetics
Methotrexate (MTX), an important anticancer and immunosuppressive agent, has been suggested for the treatment of primary biliary cirrhosis. However, the drug's pharmacodynamics and toxicity is dependent on its concentrations in plasma which in turn are directly related to MTX's elimination in the liver and kidney. Therefore, the aim of this study was to evaluate changes in MTX biliary and renal excretion during either intrahepatic or obstructive cholestasis in rats. The steady state pharmacokinetic parameters of MTX were evaluated in rats one (BDO1) or seven (BDO7) days after bile duct obstruction (BDO) or 18 h after administration of lipopolysaccharide (LPS). In comparison to the respective control groups, biliary and total clearances of MTX were decreased to 12% and 49% in the BDO1 group, to 5% and 56% in the BDO7 animals, and to 42% and 43% in the LPS group, respectively. Renal clearance of MTX was unchanged in BDO groups, but decreased to 23% of controls in the LPS animals. The serum biochemistry and expression of main hepatic MTX transporters (Mrp2, Mrp3, Mrp4, Bcrp, Oatp1a1, Oatp1a4 and Oatp1b2) confirmed the pathological cholestatic changes in the liver and partly elucidated the cause of changes in MTX pharmacokinetic parameters. In conclusion, this study is the first describing marked alteration of MTX hepatic and renal elimination induced by cholestasis in rats. Moreover, the reported changes in MTX pharmacokinetics and respective transporter expression suggest important mechanistic differences between the two widely used cholestatic models.
33
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis
Gernot Zollner, Peter Fickert, Dagmar Silbert et al. · Journal of Hepatology · 2003 · 272 citations
Medicine, Biochemistry, Pathology +15
Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles
Pauline Breedveld, Noam Zelcer, Dick Pluim et al. · Cancer Research · 2004 · 233 citations · Full text